A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).
Phase of Trial: Phase II/III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs CNP 520 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms Generation S2
- Sponsors Novartis Pharmaceuticals
- 11 Aug 2017 Status changed from not yet recruiting to recruiting.
- 02 May 2017 New trial record